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Abstract 
Healthcare associated infections (HAIs) are considered as a serious public health issues that 
contribute substantially to the global burden of mortality and morbidity with respect to infectious 
diseases. The aim is to assess the burden of healthcare associated infections by collation of 
available data from published point prevalence surveys (PPS) on HAIs to give future guidance. 
Study protocol and methodology was designed according to preferred reporting items for 
systematic reviewsand meta-analysis (PRISMA) guidelines. Published research papers that 
conducted point prevalence survey of HAIs in hospital settings by following the structured survey 
methodology employed by European Centre of Disease Prevention and Control (ECDC) were 
included. Of 1212 articles, 67 studies were included in the final analysis conducted across different 
countries. Overall, 35 studies were conducted in Europe, 21 in Asia, 9 in America, and 2 in Africa. 
The highest prevalence of HAIs was recorded in a study conducted in adult ICU settings of 75 
regions of Europe (51.3%). The majority of the studies included HAI data on urinary tract 
infections, respiratory tract infections and bloodstream infections. Klebseilla pneumonia, 
Pseudomonas aeruginosa and E. coli were the most frequent pathogens responsible for HAIs. PPS 
is useful tool to quantify HAIs and provides a robust baseline data for policy makers. However, a 
standardize surveillance method is required. In order to minimize the burden of HAIs, infection 
prevention and control programs and antibiotic stewardship may be effective strategies to 
minimize risk of HAIs. 
 
Keywords: Point prevalence surveys, Healthcare associated infections, Hospital, Infection 
presentation and control. 
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1. INTRODUCTION 
 
Globally, healthcare-associated infections (HAIs) are considered as a major health and economic 
burden, with a resultant increase in the length of hospitalization, morbidity and mortality amongst 
hospitalized patients [1-4]. Overall, HAIs are considered as the most adverse event in healthcare 
delivery [5]. Surveillance of HAIs is an integral component of any comprehensive infection 
prevention and control (IPC) program, which provides information that are necessary to highlight 
and address challenging areas [6-9]. Point-prevalence surveys (PPS) have been used for the 
surveillance of HAI for many years [10]. The pioneering project started in the 1970s by the US 
Centers for Disease Control and Prevention (CDC) who used repeated PPS to investigate the 
advantage of establishing IPC teams in US hospitals [6]. In Europe, HAI surveillance and infection 
prevention and control programs are coordinated by the European Centre for Disease Prevention 
and Control (ECDC). PPS is a time and cost effective method which estimates the burden of HAIs 
and related risk factors, especially in hospitals with limited resources [11-14]. However going 
forward, a more resource demanding and cumbersome program, i.e., prospective incidence 
surveillance, may be needed especially in high-risk specialties to help prevent HAIs [15, 16]. 
Whilst the exact global burden of HAI is unknown, estimated prevalence  rates are between 5.7%-
19.1% among low and middle income countries (LMICs) and 5.7% - 7.5% in high income 
countries [17, 18]. However, rates up to 28% to 45.8% have been reported in sub-Saharan African 
countries depending on the country and the ward surveyed [19, 20]. In 2002, the Centers for 
Disease Control and Prevention (CDC) reported approximately 1.7 million cases of HAIs in US 
hospitals [21]. In 2012, a literature review performed by ECDC documented that over 3.2 million 
patients acquire at least one HAI in Europe every year with 16 million extra days of hospitalization 
and 37,000 attributable deaths [22]. The revised European Annual Epidemiological Report (AER) 
published in 2008 reported that the overall annual burden of direct annual financial losses due to 
HAIs were estimated at approximately €7 billion [22-24]. IPC strategies provide cost-effective 
solutions as 20–30 % of HAI are avoidable [25, 26]. However, as mentioned, the risks of HAIs 
appear considerably higher in LMICs including sub-Sahara Africa, and the impact on patients and 
health-care systems is considerable and typically greatly under estimated [19, 20, 27-29]. This is 
a concern as HAIs increase the costs of patient care including additional diagnostic tests and 
therapies, prolonged hospitalization and post-discharge complications [30, 31]. Higher rates of 
HAIs in LMICs are enhanced by issues such as poor hand hygiene due for instance to heavy 
workloads, issues with infrastructure including a lack of water and blocked and leaking sinks, as 
well as poorly positioned facilities [32]. 
Overall HAIs have an appreciable impact on patients, healthcare workers, healthcare practitioner, 
and national healthcare systems. Descriptive surveys remained a useful tool for assessing 
healthcare settings and might be helpful in interpreting major issues associated with patient care 
[33]. Despite recent systematic and other reviews concerning HAIs among LMICs including sub-
Sahara African countries [4, 19, 20, 29, 34], we believe there is still an epidemiological gap 
because few resource-limited settings have accurate surveillance systems for monitoring HAIs, 
although this is improving [9]. This is important given the high rate of infectious diseases in LMICs 
including sub-Sahara Africa with its high rate of HIV, TB and malaria, misuse of antibiotics in 
hospitals and variable prevention strategies [32, 35-38]. Consequently, in order to provide a current 
summary on the prevalence of HAIs, we undertook an updated systematic review to assess the 
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prevalence of HAIs based on PPS, and to identify the type of infections and microorganisms 
responsible for HAIs to improve future care. This builds on our recent publication that reports high 
rates of HAIs in Pakistan [39]. This systematic review gathers evidences concerning the burden of 
HAI in both LMIC and HIC, which we hope will help decision makers and officials to develop a 
robust system to cope up with HAIs by investigating constraints linked to the surveillance of HAIs 
in healthcare settings as well as identify opportunities for improvement. 
2. METHODS 
A systematic review was conducted to explore point prevalence surveys for HAIs. The study 
protocol and methodology was designed according to preferred reporting items for systematic and 
meta-analysis (PRISMA) guidelines [40]. We aimed to detect point prevalence surveys worldwide 
focusing on the types of infections as well as microorganisms responsible for these various 
infections. 
2.1 Data Sources 
We retrieved relevant articles using PubMed, EBSCO, ProQuest, CINHAL and Scopus databases 
and published in English from 1995 to the present year (2019). A comprehensive grey literature 
review was also performed using Google Scholar, the World Health Organization and the website 
of the European Centre for Disease Prevention and Control in case we missed important references. 
The selected reference lists were subsequently analyzed. References of the selected articles were 
also retrieved and reviewed to again see if we had missed relevant articles from our initial search.  
2.2 Search Strategy 
Data were searched using the keywords “health-care associated infection”, “hospital-acquired 
infections”, “point prevalence”, “repeated prevalence”, “period prevalence”, “survey”, 
“hospital(s)”, “intensive care units”  by using truncations and  Boolean operators (“OR”  “AND”) 
from 1995 until April 2018. The corresponding Medical Subject Heading (MeSH) terms for the 
above keywords were also tried. Abstracts and full-text articles were screened for eligibility by 
applying PICO (population, interventions, comparison, and outcomes) approach [40].  
2.3 Inclusion and Exclusion Criteria 
In this systematic review, there was no restriction on the age or gender of the patients in the studies. 
We included English language abstracts and full-text articles on HAIs reporting three types of 
infections as well as three most frequent microorganisms responsible for HAIs. We excluded 
articles not in English. Review articles, editorials, case reports, qualitative studies, dissertations, 
as well as articles reporting the same information in a different format or Journal were also 
excluded. Studies lacking information about the types of infections were also excluded.  
2.4 Quality Assessment 
The methodological quality of included articles was assessed independently by two investigators 
(ZS and FA). For quality assessment of included articles, Newcastle-Ottawa scale (NOS) was used 
[41-43]. This scale stratifies the methodological quality of papers into three subscales, i.e. 
selection, comparability and outcomes. Differences in assessments were debated and agreed 
following a discussion with the review authors (MAH and IR). 
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2.5 Data extraction 
A data extraction form was developed. The items on the data extraction form were finalized after 
discussion amongst members of the research team. Extracted data included the authors, region, 
world bank ranking, settings, PPS methodology and protocol, population type, study duration, 
infected patients, most frequent types of infections and most frequent 3 types of microorganisms. 
Retrieved publications were subsequently filtered using the study inclusion and exclusion criteria 
by 2 independent reviewers. Data were extracted from eligible articles by assessing titles, abstracts, 
and full-text articles. 
2.6 Outcomes 
The primary outcomes of this review were to assess the world-wide prevalence of HAIs and to 
identify the types of infections and microorganism isolated responsible for HAIs. Such knowledge 
can be used to initiate pertinent activities in hospitals to improve the future management of patients 
in hospitals to reduce the prevalence of HAIs. The HAI case definitions were adopted from ECDC 
protocol [13]. As a result, HAI was defined as ‘an infection occurring in a patient during the 
process of care in a hospital or other health care facility which was not present or incubating at the 
time of admission’. For the purposes of this protocol, an infection was defined as active on the day 
of the survey when: signs and symptoms were present on the date of the survey; OR signs and 
symptoms were no longer present but the patient was still receiving treatment for that infection on 
the date of the survey. An active infection was defined as healthcare-associated when: the onset of 
the signs and symptoms was on Day 3 of the current admission or later; OR the signs and symptoms 
of an active surgical site infection were present at admission or started before Day 3, and the 
surgical site infection occurred within 30 days of a surgical intervention. 
3. RESULTS 
3.1 Literature Research 
The flow chart of the search and selection strategies of articles is illustrated in Figure 1. Through 
scientific and grey literature searches, after removal of duplicates (N=87), a total of 1212 articles 
were screened for eligibility. After screening, 290 articles were eligible for detailed assessment 
and the remaining articles not fulfilling the inclusion criteria (N=922) were excluded. Abstracts 
and full-text articles of 59 articles were not screened due to language restrictions; 87 articles did 
not provide sufficient data; 13 review articles were excluded and 64 articles did not mention the 
infection of interest. As a result, a total of 67 studies were subsequently included in the final 
analysis. 
Insert Figure 1 
The abstracts of these 67 studies, as well as full-text articles of point prevalence surveys of HAIs 
in adults and mixed populations, are summarized in Table 1, providing updated information on the 
type of infections and microorganisms. Table 2 summarizes the data on the pediatric population. 
Overall, 35 studies were conducted in Europe (33 studies on adults and 2 on pediatrics), 21 in Asia 
(19 studies on adults and 2 on pediatrics), 9 in America (5 studies on adults and 4 on pediatrics 
and 2 in Africa (adults), all reporting the proportion of overall HAIs in a mixed population of 
patients [11-14, 44-106]. The majority of point prevalence surveys were conducted in more than 
one hospital following the European Centre for Disease Control and Prevention (ECDC) protocol. 
Out of 21 studies conducted in Asia, six studies were undertaken in China [12, 76, 79, 80, 84, 85]. 
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HAIs showed a higher prevalence in intensive care units compared to other wards. The highest 
prevalence of HAIs was recorded in a study conducted in adult ICU settings among 75 regions of 
Europe (51.3%) [68]. In Asian countries, a study conducted in Turkey reported the highest 
prevalence rate of HAIs (48.7%) in ICU patients [93]. Whereas, in case of complete hospital 
survey, the highest burden of HAIs was observed in one pediatric hospital of Russia (15.1%), 
followed by Ethiopia (14.8%) and Tunisia (14.3%). The  HAI prevalence rate was 11.7% in North 
America [99, 106]. Gravel et al. performed a PPS among adult and pediatric patients separately in 
Canada showing a slightly higher prevalence rate of HAIs (10.4%) among adults in comparison to 
pediatric patients (8.0%) [11, 97]. A point prevalence study conducted in Ireland reported a higher 
HAI prevalence rate (4.3%) in long-term care facilities [49].The lowest burden of HAIs was seen 
in a study conducted in six hospitals in Greece (2.9%). 
3.2 Comparison of HAIs in HI and LMICs 
Of the 67 selected studies, 46 studies were undertaken in high-income countries (HIs), 12 studies 
in upper middle-income countries (UMICs), 8 studies were conducted in LMICs and only one 
study in low-income countries (LICs) [11-14, 44-106]. All point prevalence surveys of HAIs in 
HIs have been published since 1995. 41 of 46 studies reported a prevalence rate of <20. In LMICs, 
point prevalence surveys of HAIs have been published since 2005. Of eight studies, five studies 
reported a prevalence rate of <10% and all except one reported prevalence rate of >20%. ICU 
acquired infections are the most common and leading HAIs hospital-wide. In LMICs, the 
prevalence rate of HAIs in ICU admitted patients is <35% while in HIs the prevalence of HAIs 
exceeds 50% [65, 68, 75, 81, 103]. In our findings, the frequency of surgical site infections was 
significantly higher in LMICs when compared with the studies conducted in HIs [44, 61, 73, 83]. 
Acinetobacter species were responsible for HAIs in LMICs [81, 83, 87]. In HIs, E. coli appeared 
to be the major cause of HAIs [13, 45, 48, 52, 57]. 
3.3 Types of infections and microorganisms isolated in among pediatric patients 
The majority of published studies emphasized more than one site of infection. Regarding the types 
of infections, the majority of studies included data on urinary tract infections, respiratory tract 
infections, bloodstream infections, and surgical site infections. Among European countries, blood-
stream infections (52.6%) were one of the commonest types of infections among pediatric patient, 
followed by upper respiratory tract infections (45.0%) [102, 105]. Blood-stream infections (30.6%) 
in North America and pneumonia (65.2%) in Asia were the most frequent infections among 
pediatric patients [94, 103]. In the United States, coagulase-negative Staphylococcus (31.6% and 
19.5%) was the major cause of HAIs, followed by Enterococcus species (10.3% and 12.2%) [104, 
105]. Klebsiella pneumonia, Pseudomonasaeroginosa,andAcinetobacter species were the most 
frequent pathogens responsible for HAIs among Asian countries [14, 103]. 
3.4 Types of infections and microorganisms isolated in adults 
In Africa, surgical site infections (51.1%) were the most frequent type of infection [99]. In 
Vietnam, there were high reported rates of lower respiratory tract infections in adults (79.4%), 
whereas in Italy reported high rates of bloodstream infections (50.0%) [55, 81]. Respiratory tract 
infections were the most frequent type of infections in patients admitted to ICUs (63.5%) and in 
patients admitted to long-term care facilities in Ireland (35.0%) [49, 68]. 
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More than half of the HAIs infections are caused by gram-negative bacteria. Gram-negative 
pathogens such as Klebsiella pneumoniae, Pseudomonas aeruginosa, E. coli, and Acinetobacter 
species were the most frequently reported pathogens. Gram-positive pathogens such as 
Staphylococcus aureus and clostridium difficile were also included in these studies. 
Staphylococcus aureus, Pseudomonas aeroginosa, and Klebsiella species were the major cause of 
HAIs in Africa (20.4%, 18.3% and 22.4%) and South America the (21.6%, 12.5% and 19.2%) [98, 
99].Gram-negative bacteria were responsible for the different types of healthcare-associated 
infections in European countries (52.7%) as well as in Asian countries (67.1%) [67, 80]. In ICUs 
patients, AcinetobacterBaumannii (24.4%) was the most common pathogen responsible for HAIs 
[81]. Other publications reporting types of infections as well as types of microorganism are listed 
in Tables 1 and 2. 
Insert Tables 1 and 2. 
3.5 Quality Assessment 
The maximum of ten stars is awarded to a study. We considered study a high quality when scored 
>7, a medium quality scored 5-6 and a low quality scored 0-4. The stars that were awarded to 
studies ranged from six to nine, and the average value was 7.7 (Table 3). Most of the studies used 
ECDC protocol as a validated measurement tool to assess the prevalence of HAIs. Independent 
blind assessment was done in all studies. 
Insert Table 3 
 
4. DISCUSSION 
Healthcare-associated infections are among the most serious public health issues with substantial 
morbidity, mortality and costs [3, 20, 107, 108]. We subsequently systematically reviewed sixty-
seven studies reporting the proportion of overall HAIs in mixed patient populations. The selected 
studies conducted in various healthcare settings provide baseline information in order to develop 
future intervention research. Because of multi-factorial features of HAIs, healthcare settings are 
challenging domains in order to identify the various types of infections and microorganisms, 
especially in LMICs. Most of the studies were conducted in Europe and Asia. Two studies were 
conducted in Africa, one in Ethiopia and one in Tunisia. Previous literature surveys reported that 
HAIs remained a public health problem in LMICs compared with developed countries [29]. 
However, to date limited studies regarding PPS of HAIs have been performed in LMICs because 
of lack of national surveillance systems. The main reasons for this may include a lack of human 
and financial resources, the absence of expertise in interpretation of the data, the paucity of reliable 
diagnostic procedures, the scarcity of data obtained from patient records and the absence of 
software used for surveillance of HAIs [17].  
In Canada, Denis et al conducted prevalence surveys in both adults and pediatric settings with 
reportedly a high prevalence rate of HAIs in adults than in pediatric patients. One of the studies 
reported a 3-20 times higher neonatal infection rate in developing countries compared to developed 
countries [28]. Rezende and colleagues performed a prevalence survey in Brazil and reported 
11.4% prevalence of HAIs, requiring inter-institutional efforts so that appropriate measures could 
be taken. The frequency of endemic HAIs in neonatal ICUs in a few regions for example Brazil is 
9 times higher than in USA [29]. The higher heterogeneity in the prevalence data may be due to 
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the different study design and the selection of participants, e.g., study populations, races, and 
sample sizes, among the reviewed studies. According to the WHO, the pooled prevalence of HAIs 
in LMICs was 10.1%, while in HIs the pooled prevalence of HAIs was 7.6% [34].  Due to 
insufficient data or lack of resources in LMICs, the pooled prevalence of HAIs was significantly 
higher in LMICs than in HIs. 
Our findings indicated that lower respiratory tract infections are the leading HAIs followed by 
urinary tract infections, surgical site infections and bloodstream infections in most of the selected 
studies. A study performed in Australia reported high rates of illness from acute as well as chronic 
respiratory tract infections in the indigenous pediatric population [109]. This is important as 
pneumonia is the most frequent lower respiratory tract infection and a leading cause of death [110]. 
A study conducted in Ethiopia has reported high rates of surgical site infections. Surgical site 
infection leads to a prolonged hospital stay and increased costs of therapy [111]. In our findings, 
surgical site infections were the most frequent type of HAI in LMICs. This is similar to Allegranzi 
and his colleagues and the WHO who also reported surgical site infection as the most common 
type of HAI [17, 34].  Surgery and invasive procedures were among the significant risk factors 
responsible for surgical site infections (SSIs) [112]. To address concerns, the WHO have published 
their guidelines to ensure surgical patient’s safety which includes a safety checklist to reduce 
mortality from SSIs [113].  
The evaluation of microbiological patterns of HAIs was based on isolates of the three most 
frequent microorganisms. Gram-negative bacteria were reported as the principal causative 
pathogens in Europe and Asia [48, 57, 70, 80, 91, 93]. Our results reported that Staphylococcus 
aureus, Pseudomonas aeroginosa, and Klebsiella species were the most frequent pathogens in 
Africa and South America [99]. This is similar to a review in Africa where Klebsiella,  
Staphylococcus aureus, Pseudomonas aeroginosa and E coli were the most common organisms 
associated with healthcare-associated infections [114]. Six point prevalence studies conducted in 
China reported Pseudomonas aeruginosa as the leading cause of healthcare-associated infections 
[12, 76, 79, 80, 84, 85]. 
Overall, we believe our data provides significant information to guide policy makers to identify 
risk factors of HAIs and to devise prior strategies to reduce HAIs. In order to detect trends of HAIs, 
additional point prevalence surveys are needed, with the findings directing quality improvement 
programmes in hospitals. As part of this, proper instruction should be given to patients to identify 
and report signs and symptoms of HAIs. This intervention may help in the identification of HAIs 
during their hospital stay and after discharge. Moreover, prioritization of resources may help to 
prevent HAIs and improve patient’s safety once specific activities have been identified [115]. 
Overall, patient participation is considered as an integral part of reducing medical error and 
improving patient’s safety [116].We are aware that there will be different challenges to reduce 
HAIs between HIs and LMICs in line with the challenges to introduce effective antimicrobial 
stewardship programmes in LMICs and HIs [117]. This especially given the current lack of AMS 
programmes among a number of LMICs [118, 119]. Consequently, quality improvement 
programmes to reduce future HAIs must be tailored to the given country and situation.  
Our study has limitations that should be kept in mind when elucidating data from selected studies. 
The current systematic review utilized five databases with specific emphasis on terms describing 
point prevalence surveys of healthcare-associated infections and hospital-acquired infections. 
Limited grey literature searches were also performed using additional search terms that identified 
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relevant articles. As a result, some relevant articles may have been missed. Moreover, only English 
language studies were retrieved resulting in the exclusion of studies in other languages. In some 
studies, available information was not explained enough such as lack of information on 
microorganisms. In other studies, the analysis performed by the authors was a mixture of HAI 
prevalence data on both intensive and acute care units. Considering higher HAI prevalence rates 
in intensive care units, it could influence the differences in results. Another limitation is that lower 
reported HA prevalence does not necessarily or even often mean lower true prevalence rates - 
overall diagnostic capabilities and reporting culture can play a surprisingly large role between 
countries and cultures, leading to large differences which can be misinterpreted. The difference in 
the quality of different countries’ health-care systems and the definitions of infections had also a 
discernible influence on the systematic review. Lastly, we had divided studies into adults and 
pediatric population by considering total hospital population as adults. However, despite these 
limitations we believe our findings are robust providing direction to others. 
5. CONCLUSION  
The current systematic review provides an updated synthesis of literature concerning the overall 
burden of HAIs. These findings reported the existence of multiple pathogens responsible for 
healthcare associated infections in a variety of healthcare settings. Based on this literature review, 
standardized surveillance systems, infection prevention and control programs, multidisciplinary 
teams, instigation of antibiotic stewardship programmes, as well as the raising of awareness among 
medical staff and policy makers regarding HAIs and ways to prevent these may be effective 
strategies to minimize the future risk of HAIs. We recommend that more point prevalence surveys 
should be conducted in order to identify and target scarce resources for the prevention of future 
HAIs in all countries especially LMICs building on ongoing activities in these countries.  
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TABLE 1. Point Prevalence Surveys in mixed population 
Continent 
and 
Countries 
World 
 Bank 
Classification 
Author 
Name and 
Date 
Settings PPS 
Method 
PPS 
Protocol 
Study 
Duration 
HAIs 
(%)* 
Top Three Types of Infections 
(%)* 
Top Three types of microorganisms 
(%) 
EUROPE              
Poland [44] HI Deptula et 
al., 2017 
160 ICUs Period ECDC, 
EU-PPS 
& AU 
2012-2014 370/945 
(39.1%) 
Respiratory 
tract 
infections 
(45%) 
Bloodstream 
infections 
(14%) 
Surgical site 
infections  
(13%) 
Acinetobacter 
baumannii 
(15.2%) 
Pseudomonas 
aeruginosa 
(14.1%) 
Klebsiella 
pneumoniae 
(14.1%) 
Italy [45] HI Sticchi et al., 
2017 
18 hospitals Period ECDC 22 March-
22 April 
2016 
376/3647 
(10.3%) 
Respiratory 
tract 
infections 
(21.7%) 
Urinary tract 
infections  
(20.1%) 
Bloodstream 
infections  
(16.8%) 
E. coli 
(18.2%) 
Klebseilla 
pneumonia 
(13.4%) 
Coagulase 
negative 
staphylococcus 
(12.5%) 
Switzerland 
[46] 
HI Swissnoso,  
2017 
96 hospitals Period ECDC April-May 
2017 
763/12931 
(5.9%) 
Surgical site 
infections 
(29.0%) 
Lower 
respiratory 
tract 
infections 
(18.0%) 
Urinary tract 
infections 
(15.0%) 
Enterobacteriaceae 
(45.7%) 
Gram positive 
cocci 
(36.6%) 
Gram negative 
bacteria 
(5.5%) 
Slovenia 
[47] 
HI Klavs et al., 
2016 
21 hospitals One day ECDC October 
2011 
358/5628 
(6.3%) 
Upper 
respiratory 
tract 
infections 
(21.5%) 
Pneumonia 
(21.0%) 
Surgical site 
infection 
(18.4%) 
- - - 
Austria [48] HI Lusignani et 
al., 2016 
9 hospitals Period ECDC May- June 
2012 
268/4321 
(6.2%) 
Urinary tract 
infections 
(21.3%) 
Pneumonia 
(20.6%) 
Surgical site 
infections 
(17.4%) 
E.coli 
(10.5%) 
Enterococcus 
species 
(13.1%) 
Pseudomonas 
aeroginosa 
(11.4%) 
Ireland [49] HI Roche et al., 
2016 
24 LTCFs Period ECDC & 
HPSC 
May 2013 46/1060 
(4.3%) 
Respiratory 
tract 
infections 
(35.0%) 
Skin 
infections 
(35.0%) 
Urinary tract 
infections 
(12.0%) 
- - - 
Slovakia 
[50] 
HI Stefkovicova 
et al.,  2015 
40 hospital Period ECDC June 2012 298/8397 
(3.5%) 
Urinary tract 
infections 
(26.2%) 
Surgical site 
infections 
(15.7%) 
Blood stream 
infections 
(9.9%) 
E.coli. 
(15.0%) 
Klebsiella 
species 
(12.5%) 
Pseudomonas 
aeroginosa 
(10.8%) 
France [51] HI Milliani et 
al., 
2015 
4 HCS Period France 
National 
PPS 
14 May- 
21 June 
2012 
403/5954 
(6.8%) 
Urinary tract 
infections 
(26.6%) 
Skin and soft 
tissue 
infections 
(17.6%) 
Surgical site 
infections 
(15.0%) 
Enterobacteiaceae 
(41.0%) 
Gram positive 
cocci 
(40.0%) 
Stapgylococcus 
aureus 
(21.0%) 
19 Countries 
[53] 
HI Katrien et 
al., 2014 
1181 
LTCFs 
Period ECDC April-May 
2013 
2626/77264 
(3.4%) 
Respiratory 
tract 
infections 
(31.2%) 
Urinary tract 
infections 
(31.2%) 
Skin 
infections 
(22.8%) 
E. coli 
(34.4%) 
Staphylococcu
s aureus 
(10.2%) 
Proteus Mirabilis 
(8.1%) 
28 Countries 
[52] 
HI Katrien et 
al., 2014 
722 LCTF Period ECDC May- 
September 
2010 
2495/61932 
(4.0%) 
Respiratory 
tract 
infections 
(33.6%) 
Urinary tract 
infections 
(22.3%) 
Skin 
infections 
(21.4%) 
E.coli 
(38.3%) 
Staphylococcu
s aureus 
(13.5%) 
Proteus mirabilis 
(9.9%) 
12 Countries 
[54] 
HI Erdam et al., 
2014 
88 ICUs One day CDC Between 
June- July 
2012 /one 
day 
305/749 
(40.7%) 
Pneumonia 
(53.4%) 
Bloodstream 
infections 
(18.3%) 
Urinary tract 
infections 
(30.7%) 
Gram negative 
bacilli 
(20.3%) 
Acinetobacter 
species 
(15.4%) 
Pseudomonas 
aeruginosa 
(9.5%) 
16 
 
Italy [55] HI Sinatra et al., 
2013 
3 
departments 
One day ECDC September 
2011 
12/328 
(3.6%) 
Blood stream 
infections 
(50.0%) 
Urinary tract 
infections 
(28.5%) 
- - - - 
Ireland [56] HI Smiddy et 
al., 2013 
8 units Period Own 2006-2009 23/754 
(3.0%) 
Bloodstream 
infections 
(25.0%) 
Surgical site 
infections 
(25.0%) 
Urinary tract 
infections 
(20.8%) 
- - - 
Germany 
[57] 
HI Behnke et 
al., 2013 
132 
hospitals 
Period ECDC September- 
October 
2011 
2109/41539 
(5.1%) 
Surgical site 
infections 
(24.3%) 
Urinary tract 
infections 
(23.2%) 
Respiratory 
tract 
infections 
(21.7%) 
E.coli 
(18.0%) 
Enterococci 
(13.2%) 
Staphylococcus 
aureus 
(13.1%) 
33 Countries 
[58] 
HI Carl Suetens 
et al., 
2013 
947 
hospitals 
Period ECDC 2011-2012 13829/2314
59 
(5.9%) 
Respiratory 
tract 
infections 
(23.5%) 
Surgical site 
infections 
(19.6%) 
Urinary tract 
infections 
(19.0%) 
E. coli 
(15.9%) 
Staphylococcu
s aureus 
(12.3%) 
Enterococcus 
species 
(9.6%) 
23 Countries 
[13] 
HI Zarb et al.,  
2012 
66 hospitals Period ECDC May 2010- 
October 
2010 
1408/19888 
(7.0%) 
Pneumonia 
(25.7%) 
Surgical site 
infections 
(18.9%) 
Urinary tract 
infections 
(17.2%) 
E. coli 
(15.2%) 
Staphylococcu
s aureus 
(12.1%) 
Pseudomonas 
aeroginosa 
(11.2%) 
Germany 
[59] 
HI Heudorf et 
al., 
2012 
40 nursing 
homes 
Period HALT January 5,- 
Mach 9, 
2011  
161/3732 
(4.3%) 
Urinary tract 
infections 
(28.0%) 
Respiratory 
tract 
infections 
(25.5%) 
Skin 
infections 
(15.5%) 
- - - 
London [60] HI Coello et al., 
2011 
5 hospitals Period ESAC July 2009 104/1354 
(7.7%) 
Surgical site 
infections 
(18.2%) 
Urinary tract 
infections 
(18.2%) 
Bloodstream 
infections 
(14.0%) 
- - - 
France [61] HI Lietard et al., 
2011 
2337 
healthcare 
facilities 
One day CDC 2006 12182/1997
16 
(6.1%) 
Urinary tract 
infections 
(2.4%) 
Pneumonia 
(2.4%) 
Surgical site 
infections 
(0.8%) 
E.coli 
(28%) 
Staphylococcu
s aureus 
(18.2%) 
Pseudomonas 
aeruginosa 
(9.5%) 
Greece [62] HI Alexopoulos 
et al., 2011 
6 hospitals One day CDC December 
2005- 
February 
2006 
64/2180 
(2.9%) 
Urinary tract 
infections 
(34.2%) 
Lower 
respiratory 
tract 
infections 
(14.3%) 
Bloodstream 
infections 
(14.3%) 
E. coli 
(14.3%) 
Pseudomonas 
areuginosa 
(10%) 
Enterococcus 
species 
(8.6%) 
England [63] HI Hopkins et 
al., 2011 
103 
organization 
Period ECDC September-
November 
2011 
3360/52443 
(6.4%) 
Respiratory 
tract 
infections 
(22.8%) 
Urinary tract 
infections 
(17.2%) 
Surgical site 
infections 
(15.7%) 
Enterobacteriaciae 
(14.1%) 
Staphylococcu
s aureus 
(6.7%) 
Closridium 
difficile 
(5.4%) 
Scotland 
[64] 
HI Cairns et al., 
2011 
45 hospital Period CDC 2005-2006 1094/11090 
(9.8%) 
Urinary tract 
infections 
(17.9%) 
Surgical site 
infections 
(15.7%) 
Gastrointestin
al infections 
(15.5%) 
- - - 
Scotland 
[65] 
HI Cairns et al., 
2010 
29 ICUs Period Own October 
2005-
September 
2006 
35/129 
(27.1%) 
Lower 
respiratory 
tract 
infections 
(23.9%) 
Surgical site 
infections 
(23.9%) 
Pneumonia 
(19.5%) 
- - - 
Belgium [66] HI Gordts et al., 
2010 
63 hospitals Period CDC October – 
November 
2007 
1037/17343 
(5.9%) 
Urinary tract 
infections 
(23.9%) 
Lower 
respiratory 
tract 
infections 
(20.0%) 
Surgical site 
infections 
(14.6%) 
- - - 
17 
 
Italy [67] HI Lanini et al., 
2009 
51 hospitals Period CDC 2002-2004 589/9609 
(6.1%) 
Lower 
respiratory 
tract 
infections 
(35.8%) 
Urinary tract 
infections 
(23.6%) 
Bloodstream 
infections 
(14.0%) 
Gram negative 
bacteria 
(52.7%) 
Gram positive 
bacteria 
(38.8%) 
Fungi 
(5.0%) 
75 Countries 
[68] 
HI Vincet et al., 
2009 
1265 ICUs One day CDC 2006-2007 7087/13796 
(51.3%) 
Respiratory 
tract 
infections 
(63.5%) 
Abdominal 
infections 
(19.6%) 
Bloodstream 
infections 
(15.0%) 
Staphylococcus 
aureus 
(20.5%) 
E .coli 
(16.0%) 
Pseudomonas 
species 
(19.9%) 
France [69] HI Patte et al., 
2005 
Homecare 
Setting 
(HCS) 
One day Own June 5, 
2000 
23/376 
(6.1%) 
Urinary 
Tract 
Infections 
(50.0%) 
Skin 
Infections 
(37.9%) 
- E. coli 
(29.4%) 
Staphylococcu
s aureus 
(29.4%) 
Enterococcus 
species 
(17.6%) 
Italy [70] HI Lizioli et al., 
2003 
88 hospitals Period Own February-
March 
2000 
916/18667 
(4.9%) 
Urinary tract 
infections 
(33.6%) 
Pneumonia 
(22.6%) 
Surgical site 
infections 
(15.0%) 
E.coli 
(16.8%) 
Staphylococcu
s aureus 
(15.0%) 
Pseudomonas 
aeruginosa 
(13.2%) 
Greece [71] HI Starakis et 
al., 2002 
19 units Period CDC 1998 and 
1999 
97/997 
(9.7%) 
Lower 
respiratory 
tract 
infections 
(36.0%) 
Urinary tract 
infections 
(25.8%) 
Bloodstream 
infections 
(19.6%) 
Pseudomonas 
aeroginosa 
(20.6%) 
Kelbsiella 
pneumonia 
(8.2%) 
Staphylococcus  
(7.2%) 
Greece [72] HI Gikas et al., 
2002 
14 hospitals One day CDC November 
16, 1999 
337/3925 
(8.6%) 
Lower 
respiratory 
tract 
infections 
(30.3%) 
Urinary tract 
infections 
(22.7%) 
Bloodstream 
infections 
(15.8%) 
Pseudomonas 
aeroginosa 
(16.6%) 
E. coli 
(10.8%) 
Klebsiella 
pneumoniae 
(10.3%) 
France [73] HI Group et al., 
2000 
830 
hospitals 
Period Own May 20 - 
June 21 
1996 
15798/2363
34 
(6.7%) 
Urinary tract 
infections 
(0.19%) 
Lower 
respiratory 
tract 
infections 
(0.07%) 
Surgical site 
infections 
(0.06%) 
E. coli 
(20%) 
Staphylococcu
s aureus 
(16%) 
Pseudomonas 
aeroginosa 
(11%) 
Switzerland 
[74] 
HI Pittet et al., 
1999 
4 hospitals One week CDC May 1996  156/1349 
(11.6%) 
Surgical site 
infections 
(30.0%) 
Urinary tract 
infections 
(22.0%) 
Respiratory 
tract 
infections 
(15.0%) 
Enterobacteriaceae 
(28.0%) 
Staphylococcu
s aureus 
(13.0%) 
Pseudomonas 
aeruginosa 
(11.0%) 
17 Countries 
[75] 
HI Vincent et 
al., 1995 
1417 ICUs One day Own April 28-
April 29, 
1992 
4501/10038 
(44.8%) 
Pneumonia 
(46.9%) 
Lower 
respiratory 
tract 
infections 
(17.8%) 
Urinary tract 
infections 
(17.6%) 
Enterobacteriaceae 
(34.4%) 
Staphylococcu
s aureus 
(30.1%) 
Pseudomonas 
aeroginosa 
(28.7%) 
ASIA              
China [76] UMI Chen et al., 
2017 
52 hospitals One day NHFPC October 
2014-
March 
2015 
1998/53939 
(3.7%) 
Lower 
respiratory 
tract 
infections 
(47.2%) 
Urinary tract 
infections 
(12.3%) 
Upper 
respiratory 
tract 
infections 
(11.0%) 
Pseudomonas 
aeroginosa 
(9.4%) 
Acinetobacter
Baumanni 
(7.9%) 
Klebsiellapnuem
oniae 
(7.3%) 
India [77] LMI Nair et al., 
2017 
1 hospital Period  CDC March 
2014-
August 
2014 
71/1886 
(3.7%) 
Surgical site 
infections 
(23.9%) 
Pneumonia  
(18.3%) 
Upper 
respiratory 
tract 
infections 
- - - 
18 
 
(16.9%) 
Singapore 
[78] 
HI Cai et al., 
2017 
13 hospitals Period ECDC July 2015- 
February 
2016 
646/5415 
(11.9%) 
Clinical 
sepsis 
(25.5%) 
Pneumonia 
(24.8%) 
- Staphylococcus 
aureus 
(12.9%) 
Pseudomonas 
aeroginosa 
(11.5%) 
- 
China [79] UMI Liu et al., 
2016 
124 
hospitals  
One day BNICC May 2014 1294/61990 
(2.0%) 
Urinary tract 
infections 
(15.0%) 
Gastrointesti
nal 
infections 
(7.7%) 
Surgical site 
infections 
(6.3%) 
Pseudomonas 
aeruginosa 
(13.8%) 
Acinetobacter
baumannii 
(12.9%) 
E.Coli 
(12.6%) 
China [80] UMI Zhang et al., 
2016 
43 clinical 
departments 
Period CDC May 2012-
May 2014 
147/4029 
(3.6%) 
Respiratory 
tract 
infections 
(54.8%) 
Urinary tract 
infections 
(21.4%) 
Blood stream 
infections 
(7.1%) 
Gram negative 
bacteria 
(67.1%) 
Gram positive 
bacteria 
(20.3%) 
Fungi 
(10.5%) 
Vietnam [81] LMI Phu et al., 
2016 
14 ICUs One day 
each 
month 
ECDC October 
2012- 
October 
2013 
965/3266 
(29.5%) 
Lower 
respiratory 
tract 
infections 
and 
pneumonia 
(79.4%) 
Bloodstream 
infections 
(4.4%) 
Surgical site 
infections 
(4.2%) 
Acinetobacter 
baumannii 
(24.4%) 
Pseudomonas 
aeroginosa 
(13.8%) 
Klebsiella 
pneumoniae 
(11.6%) 
Japan [82] HI Morioka et 
al., 
2015 
1 Hospital One day ECDC July 3, 
2014 
85/841 
(10.1%) 
Pneumonia  
(20.0%) 
Surgical site 
infections 
(19.0%) 
Blood stream 
infections 
 (11.1%) 
Enterobacteriaceae 
(27.6%) 
Staphylococcu
s aureus 
(15.5%) 
Enterococcuss 
(10.3%) 
India [83] LMI Kumar et al., 
2014 
1 Hospital One day CDC 2008 and 
2011 
125/1834 
(6.8%) 
Surgical site 
infections 
(33.0%) 
Upper 
respiratory 
tract 
infections 
(26.0%) 
Pneumonia 
(24.0%) 
Klebsiella 
pneumonia 
(15.0%) 
Pseudomonas 
aeruginosa 
(15.0%) 
Acinetobactercal
cobaumanni 
(2.4%) 
China [84] UMI Tao et al., 
2014 
48 wards One day US CDC November 
13,2013 
86/2434 
(3.5%) 
Respiratory 
tract 
infections 
(49.4%) 
Surgical Site 
infections 
(22.9%) 
Gastrointestin
al infections 
(9.2%) 
Pseudomonas 
aeruginosa 
(24.0%) 
Klebseilla 
pneumonia 
(14.0%) 
E. coli 
(14.0%) 
China [85] UMI Xie et al., 
2013 
5 
departments 
Period NISS 2007-2011 287/9533 
(3.0%) 
Respiratory 
tract 
infections 
(74.1%) 
Urinary tract 
infections 
(8.9%) 
Surgical site 
infections 
(5.9%) 
Pseudomonas 
aeruginosa 
(10.4%) 
E.coli 
(5.9%) 
Acinetobacter 
baumannii 
(5.9%) 
Iran [86] UMI Askarian et 
al., 2012   
8 hospitals Period NNIS 2008-2009 323/3450 
(9.4%) 
Bloodstream 
infections 
(26.6%) 
Surgical site 
infections 
(25.7%) 
Urinary tract 
infections 
(14.9%) 
- - - 
Vietnam [87] LMI Thu et al., 
2011 
36 hospitals Period CDC February 
2008- 
December 
2009 
553/7571 
(7.3%) 
Pneumonia 
(41.9%) 
Surgical site 
infections 
(27.5%) 
- Pseudomonas 
aeruginosa 
(31.5%) 
Acinetobacter
baumannii 
(23.3%) 
- 
Mongolia[88
] 
LMI Ider et al., 
2010 
2 hospitals One day US CDC September 
2008 
50/933 
(5.3%) 
Respiratory 
tract 
infections 
(24%) 
Urinary tract 
infections 
(20%) 
Surgical site 
infections 
(20%) 
- - - 
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China [12] UMI Xie et al., 
2010 
13 hospitals Period CDC November, 
2007-
November, 
2008 
790/20350 
(3.9%) 
Respiratory 
tract 
infections 
(63.1%) 
Surgical site 
infections 
(9.6%) 
Urinary tract 
infections 
(8.6%) 
Pseudomonas 
aeruginosa 
(16.4%) 
E.coli 
(10.5%) 
Klebsiella 
pneumoniae 
(7.9%) 
Hong Kong 
[89] 
HI Lee et al., 
2007 
1 hospital One day CDC September 
7,2005 
41/1021 
(4.0%) 
Pneumonia 
(33%) 
Surgical site 
infections 
(26.2%) 
Bloodstream 
infections 
(21.4%) 
Pseudomonas 
aeroginosa 
(N/A) 
Staphylococcu
s aureus 
(N/A) 
- 
Saudi Arabia 
[90] 
HI Balkhy et al., 
2006 
7 units One day Own May 2003 38/562 
(6.7%) 
Bloodstream 
infections 
(31.1%) 
Ventilator 
acquired 
pneumonia 
(28.9%) 
Urinary tract 
infections 
(24.4%) 
Pseudomonas 
species 
(20.9%) 
Enterococcuss 
species 
(18.9%) 
Klebsiella 
pneumoniae 
(13.7%) 
Thailand 
[91] 
LMI Danchaivijitr
et al., 2005 
42 hospitals Two 
week 
Own March 12- 
March 25 
2001 
1181/18456 
(6.4%) 
Lower 
respiratory 
tract 
infections 
(34.0%) 
Urinary tract 
infections 
(21.5%) 
Surgical site 
infections 
(15.0%) 
Pseudomonas 
aeruginosa 
(19.8%) 
Klebsiella 
pneumonia 
(13.5%) 
Acinetobacter 
species 
(13.0%) 
Malaysia 
[92] 
UMI Hughes et 
al., 2005 
5 clinical 
departments 
Period CDC July 16-17, 
2001 
75/538 
(13.9%) 
Clinical 
sepsis 
(22.4%) 
Pneumonia 
(21.4%) 
Urinary tract 
infections 
(12.2%) 
Pseudomonas 
aeruginosa 
(17.4%) 
MRSA 
(15.5%) 
MSSA 
(8.7%) 
Turkey [93] UMI Esen et al., 
2004 
56 ICUs One day CDC September 
19, 2001 
115/236 
(48.7%) 
Pneumonia 
(28.0%) 
Blood stream 
infections 
(23.3%) 
Urinary tract 
infections 
(15.7%) 
Pseudomonas 
aeroginosa 
(20.8%) 
Staphylococcu
s aureus 
(18.2%) 
Acinetobacter 
species (18.2%) 
AMERICAs              
Canada 
[106] 
HI Taylor et al., 
2016 
49 hospitals One day NHSN February 
2009 
1173/9953 
(11.7%) 
Urinary tract 
infections 
(34.8%) 
Pneumonia 
(21.8%) 
Surgical site 
Infections 
(17.4%) 
- - - 
Florida [95] HI Magill et al., 
2012 
9 hospitals One day NHSN August 
2009 
51/851 
(6.0%) 
Surgical site 
infections 
(31.0%) 
Pneumonia 
(15.5%) 
Urinary tract 
infections 
(15.5%) 
Staphylococcus 
aureus 
(15.5%) 
Candida 
species 
(10.3%) 
Pseudomonas 
aeruginosa 
(8.6%) 
USA [96] HI Magill et al., 
2014 
183 
hospitals 
One day NHSN May-
September 
2011 
452/11282 
(4.0%) 
Pneumonia 
(21.8%) 
Surgical site 
infections 
(21.8%) 
Gastrointestin
al infections 
(17.1%) 
Clostridium 
difficile 
(12.1%) 
Staphylococcu
s aureus 
(10.7%) 
Klebsiella 
pneumonia 
(9.9%) 
              
Canada [97] HI Gravel et al., 
2007 
25 hospitals Period CDC February 5 
– February 
8 2001 
601/5750 
(10.4%) 
Urinary tract 
infections 
(3.4%) 
Pneumonia 
(3.0%) 
Surgical site 
infections 
(2.5%) 
Coagulase 
negative 
staphylococcus 
(N/A) 
Gram negative 
bacteria 
(N/A) 
Gram positive 
bacteria 
(N/A) 
Brazil [98] UMI Rezende et 
al., 1998 
11 hospitals Period CDC & 
NNIS 
August – 
October 
1992 
267/ 2339 
(11.4%) 
Pneumonia 
(19.5%) 
Surgical site 
infections 
(19.2%) 
Urinary tract 
infections 
(13.1%) 
Staphylococcus 
aureus 
(21.6%) 
E.coli 
(21.6%) 
Pseudomonas 
species 
(12.5%) 
AFRICA              
Ethiopia [99] LI Yallew et al., 
2016 
2 hospitals Period CDC March- 
July 2015 
135/908 
(14.8%) 
Surgical site 
infections 
(51.1%) 
Pneumonia 
(25.0%) 
Blood stream 
infections 
(19.0%) 
Klebseilla species 
(22.4%) 
Staphylococcu
s aureus 
(20.4%) 
Pseudomonas 
aeruginosa 
(18.3%) 
Tunisia 
[100] 
LMI Kallel et al., 
2005 
15 
departments 
One day Own April 17-
april 18 
2002 
50/280 
(14.3%) 
Pneumonia 
(32.0%) 
Surgical site 
infections 
(28.0%) 
Urinary tract 
infections 
(20.0%) 
Klebsiella 
pneumoniae 
(23.1%) 
Pseudomonas 
aeroginosa 
(19.2%) 
Acinetobacterbau
mannii 
(15.4%) 
20 
 
*Percentages of total infections, E.coli= Escherichia coli, N/A= Not Available, LMI= low middle income and low income country, HI= High Income country, UMI= Upper middle income country, CDC= Centre for Disease Prevention 
and Control, ECDC= European Centre for Disease Prevention and Control, NHSN= National Healthcare Safety Network, HELICS= Hospital in Europe Link for Infection Control through Surveillance, EU-PPS-AU= Europe Union 
Point Prevalence Surveys and Antibiotic Use Protocol, HPSC= Health Protection Surveillance Centre, HALT= Healthcare associated infections in Long Term care Facilities project, ESAC= European Surveillance of Antibiotic 
consumption, NHFPC= National Health and Family Planning Commission Centre, BNICC= Beijing Nosocomial infection Surveillance system,  
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TABLE 2. Point Prevalence Surveys in Pediatrics 
Continent 
and 
Countries 
World 
 Bank 
Classificatio
n 
Author 
Name and 
Date 
Settings PPS 
Method 
PPS 
Protocol 
Study 
Duration 
HAIs 
(%)* 
Top Three Types of Infections 
(%)* 
Top Three types of microorganisms 
(%) 
EUROPE              
29 Countries 
[101] 
HI Zingget al., 
2017 
1149 
hospitals 
Period ECDC May 2011-
November 
2012 
726/17273 
(4.2%) 
Bloodstream 
infections 
(45%) 
Lower 
respiratory 
infections 
(22.0%) 
Gastronintesti
nal infection 
(8.0%) 
Enterobacteriacea 
(15.0%) 
- - 
Russia [102] UMI Hajdu et al., 
2007 
1 hospital One day HELICS February 
2006 
60/395 
(15.1%) 
Upper 
respiratory 
tract 
infections 
(45.0%) 
Lower 
respiratory 
tract 
infections 
(19.0%) 
Urinary tract 
infections 
(12.0%) 
- - - 
ASIA              
Vietnam [103] LMI Le et al., 
2016 
ICUs One 
day/once 
in a 
month 
ECDC October 
2012- 
September 
2013 
454/1363 
(33.3%) 
Pneumonia 
(65.2%) 
Blood stream 
infections 
(26.1%) 
Surgical site 
infections 
(2.0%) 
Klebseilla 
pneumonia 
(19.0%) 
Pseudomonas 
species 
(18.0%) 
Acinetobacter 
species 
(15.0%) 
Turkey [14] UMI Kepenekliet 
al., 2015 
50 ICUs One day CDC September 
2012 
122/327 
(37.3%) 
Lower 
respiratory 
tract 
infections 
(55.3%) 
Blood stream 
infections 
(27.3%) 
Urinary tract 
infections 
(7.1%) 
Pseudomonas 
aeruginosa 
(24.0%) 
Acinetobacter 
species 
(15.0%) 
Candida species 
(7.0%) 
AMERICA              
Canada [94] HI Rutledge-
Taylor et al., 
2012 
30 hospitals One day CDC February 3, 
2009 
118/1353 
(8.7%) 
Bloodstream 
infections 
(30.6%) 
Pneumonia 
(16.1%) 
Viral 
gastroenteritis 
(13.7%) 
Coagulase 
negative 
staphylococcus 
(47.4%) 
Pseudomonas 
aeroginosa 
(35.0%) 
Candida species 
(30.8%) 
Canada [11] HI Gravel et al., 
2007 
25 hospitals One day CNISP February 5 
– February 
8 2001 
80/997 
(8.0%) 
Blood stream 
infections 
(37.5%) 
Pneumonia 
(26.2%) 
Urinary tract 
infections 
(12.5%) 
Coagulase 
negative 
staphylococcus 
(NA) 
Gram negative 
bacteria 
(NA) 
Gram positive 
bacteria 
(NA) 
US [104] HI Grohskopfet 
al., 2002 
31 hospitals One day Own August 
1999 
61/512 
(11.9%) 
Bloodstream 
infections 
(41.3%) 
Respiratory 
tract 
infections 
(22.6%) 
Urinary tract 
infections 
(13.3%) 
Coagulase 
negative 
staphylococcus 
(19.5%) 
Enterococcus 
(12.2%) 
Staphylococcus 
aureus 
(11.0%) 
US [105] HI Sohn et al., 
2001 
29 Neonatal 
intensive 
care units 
One day Own August 9, 
2000 
94/827 
(11.3%) 
Bloodstream 
infections 
(52.6%) 
Respiratory 
tract 
infections 
(12.9%) 
Urinary tract 
infections 
(8.6%) 
Coagulase 
negative 
staphylococcus 
(31.6%) 
Enterococci 
(10.3%) 
E.coli 
(8.5%) 
*Percentages of total infections, E.coli= Escherichia coli, N/A= Not Available, LMI= low and low middle income country, HI= High Income country, UMI= Upper middle income country, , CDC= Centre for Disease Prevention and 
Control, ECDC= European Centre for Disease Prevention and Control, HELICS= Hospital in Europe Link for Infection Control through Surveillance, CNISP= Canadian Nosocomial Infection Surveillance Programs 
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Table 3. Quality assessment of included articles  
 Selection Comparability Outcomes  
Studies Representatives of 
sampleA 
Sample 
sizeB 
Non-
respondentsC 
Ascertainment 
of exposureD 
Based on design 
and analysisE 
Assessment of 
outcomesF 
Statistical 
testG 
Quality score 
Deptula et al., 
2017 [44] 
* * - * ** ** * 8 
Sticchi et al., 
2017 [45] 
* * - * ** ** * 8 
Swissnoso,  
2017 [46] 
* * - * ** ** * 8 
Klavs et al., 
2016 [47] 
* * - ** * ** * 8 
Lusignani et 
al., 2016 [48] 
* * - * ** ** - 7 
Roche et al., 
2016 [49] 
* * - * * ** - 6 
Stefkovicova 
et al.,  2015 
[50] 
* * - * ** ** - 7 
Milliani et al., 
2015 [51] 
* * - * ** ** * 8 
Katrien et al., 
2014[53] 
* * - ** ** ** - 8 
Katrien et al., 
2014[52] 
* * - ** ** ** * 9 
Erdam et al., 
2014[54] 
* * - * ** ** * 8 
Sinatra et al., 
2013 [55] 
* * - * * ** * 7 
Smiddy et al., 
2013 [56] 
* * - * * ** * 7 
Behnke et al., 
2013 [57] 
* * - ** ** ** * 9 
Carl Suetens 
et al., 
2013[58] 
* * - ** ** ** * 9 
Zarb et al.,  
2012[13] 
* * - * ** ** * 8 
Heudorf et al., 
2012 [59] 
* * - * * ** * 7 
Coello et al., 
2011 [60] 
* * - * * ** - 6 
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Lietard et al., 
2011 [61] 
* * - * ** ** - 7 
Alexopoulos 
et al., 2011 
[62] 
* * - * ** ** - 7 
Hopkins et al., 
2011 [63] 
* * - * ** ** * 8 
Cairns et al., 
2011 [64] 
* * - * * ** * 7 
Cairns et al., 
2010 [65] 
* * - * * ** * 7 
Gordts et al., 
2010 [66] 
* * - ** * ** * 8 
Lanini et al., 
2009 [67] 
* * - * ** ** * 8 
Vincet et al., 
2009[68] 
* * - * ** ** * 8 
Patte et al., 
2005 [69] 
* * - * * ** * 7 
Lizioli et al., 
2003 [70] 
* * - * ** ** - 7 
Starakis et al., 
2002 [71] 
* * - * ** ** - 7 
Gikas et al., 
2002[72] 
* * - ** * ** * 9 
Group et al., 
2000 [73] 
* * - ** ** ** * 9 
Pittet et al., 
1999[74] 
* * - ** ** ** * 9 
Vincent et al., 
1995[75] 
* * - ** ** ** - 8 
Chen et al., 
2017 [76] 
* * - * ** ** * 8 
Nair et al., 
2017 [77] 
* * - ** * ** * 8 
Cai et al., 
2017 [78] 
* * - * * ** * 7 
Liu et al., 
2016 [79] 
* * - ** ** ** * 9 
Zhang et al., 
2016 [80] 
* * - * ** ** * 8 
Phu et al., 
2016 [81] 
* * - * ** ** * 8 
Morioka et al., 
2015 [82] 
* * - ** ** ** * 9 
24 
 
Kumar et al., 
2014 [83] 
* * - * ** ** - 7 
Tao et al., 
2014 [84] 
* * - ** ** ** * 9 
Xie et al., 
2013 [85] 
* * - * ** ** * 8 
Askarian et 
al., 2012   [86] 
* * - * * ** * 7 
Thu et al., 
2011 [87] 
* * - ** * ** * 8 
Ider et al., 
2010[88] 
* * - * * ** * 7 
Xie et al., 
2010[12] 
* * - * ** ** * 8 
Lee et al., 
2007[89] 
* * - * * ** * 7 
Balkhy et al., 
2006[90] 
* * - * ** ** * 8 
Danchaivijitret 
al., 2005 [91] 
* * - * ** ** - 7 
Hughes et al., 
2005 [92] 
* * - ** ** ** * 9 
Esen et al., 
2004 [93] 
* * - * ** ** * 8 
Taylor et al., 
2016 [106] 
* * - * * ** * 7 
Magill et al., 
2012 [95] 
* * - * ** ** * 8 
Magill et al., 
2014 [96] 
* * - * ** ** * 8 
Gravel et al., 
2007[97] 
* * - * ** ** * 8 
Rezende et al., 
1998 [98] 
* * - * ** ** * 8 
Yallew et al., 
2016 [99] 
* * - ** ** ** * 9 
Kallel et al., 
2005 [100] 
* * - * ** ** * 8 
Zingg et al., 
2017[101] 
* * - * * ** * 7 
Hajdu et al., 
2007 [102] 
* * - * * ** * 7 
Le et al., 2016 
[103] 
* * - * ** ** * 8 
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Kepenekli et 
al., 2015 [14] 
* * - * ** ** * 8 
Rutledge-
Taylor et al., 
2012 [94] 
* * - * ** ** * 8 
Gravel et al., 
2007[11] 
* * - * ** ** * 8 
Grohskopf et 
al., 2002 [104] 
* * - * ** ** * 8 
Sohn et al., 
2001 [105] 
* * - * ** ** * 8 
A: *= truly representative of average in target population or somewhat representative of average in target population 
B: *=justified or satisfactory, -- = not justified 
C: *=satisfactory response rate, --= unsatisfactory or no description 
D: **=validated measurement tool, *=non validated measurement tool, --= no description of measurement tool 
E: **=confounding factors, *incomplete information, --= no information 
F: **=independent blinded assessment or record linkage, *=self-report, --= no description 
G: *=Yes, --=No 
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Figure 1. Flow chart and selection strategies of studies. 
 
 
 
 
 
 
 
 
